Press Releases April 21, 2026 04:10 PM

Compass Diversified Announces First Quarter 2026 Earnings and Conference Call Information

Compass Diversified announces Q1 2026 earnings release and upcoming conference call.

By Avery Klein
Share
Twitter Reddit Facebook LinkedIn
CODI

Compass Diversified (NYSE: CODI), a middle-market branded consumer and industrial business owner, plans to report its Q1 2026 financial results after market close on May 6, 2026, with a conference call scheduled to discuss results and provide 2026 business outlook updates. The company cautions on forward-looking statements and associated risks.

Compass Diversified Announces First Quarter 2026 Earnings and Conference Call Information
CODI
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Compass Diversified will release its Q1 2026 earnings on May 6, 2026, after market close.
  • A conference call will take place the same day to review financial results and the 2026 outlook.
  • The company provides cautionary forward-looking statements highlighting risks and uncertainties affecting future performance.

WESTPORT, Conn., April 21, 2026 (GLOBE NEWSWIRE) -- Compass Diversified (NYSE: CODI) (“CODI” or the “Company”), an owner of leading middle-market branded consumer and industrial businesses, announced today that it plans to report financial results for the first quarter ended March 31, 2026 on Wednesday, May 6, 2026 after market close. The Company has scheduled a conference call at 5:00 p.m. ET on May 6, 2026 to review its first quarter financial results and provide an update on its 2026 business outlook.

A live webcast of the call will be available on the Investor Relations section of CODI’s website. To avoid delays, participants are encouraged to log into the webcast 15 minutes before the scheduled start time. A replay of the webcast will also be available for a limited time on the Company’s website.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 134, as amended, including without limitation, CODI’s expectations regarding the timing of a conference call to discuss its fourth quarter and full year 2025 results, CODI’s expectations with respect to the delivery of its financial results and the future performance of CODI and its subsidiaries. Such forward looking statements may be identified by, among other things, the use of forward-looking terminology such as “believe,” “expect,” “may,” “could,” “would,” “plan,” “intend,” “estimate,” “predict,” “potential,” “continue,” “should” or “anticipate” or the negative thereof or other variations thereon or comparable terminology, or by discussions of strategy that involve risks and uncertainties. These statements are based on beliefs and assumptions by CODI’s Board of Directors and management, and on information currently available to CODI’s Board of Directors and management. These statements involve risk and uncertainties that could cause CODI’s actual results and outcomes to differ, perhaps materially. Please see CODI’s Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC on February 27, 2026 for other risk factors that you should consider in connection with such forward-looking statements. Investors are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date such statements have been made. Except as required by law, CODI does not undertake any public obligation to update any forward-looking statements to reflect events, circumstances, or new information after the date of this press release, or to reflect the occurrence of unanticipated events.

Investor Relations

Compass Diversified
[email protected]


Risks

  • Forward-looking statements involve risks and uncertainties that could materially affect actual results.
  • Dependence on performance of multiple middle-market branded consumer and industrial businesses.
  • External economic and market conditions may impact Compass Diversified's future outcomes.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026